NRx Pharmaceuticals Expands NRX-101 Development to Include Combination Therapy with Transcranial Magnetic Stimulation for Depression
核心洞察
NRx Pharmaceuticals has amended its Investigational New Drug filing for NRX-101 to include use with Transcranial Magnetic Stimulation (TMS) for treating depression (搜索), including suicidal depression (搜索).
Recent clinical studies show D-cycloserine combined with TMS achieved over 80% response rates compared to 30% success rates with SSRI antidepressants alone.
The company anticipates more than 1 million Americans per year may be treated with TMS by 2030, creating a substantial new market opportunity for NRX-101.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced on December 3, 2025, that it has amended its Investigational New Drug filing for NRX-101 (D-cycloserine/lurasidone) to include use in combination with Transcranial Magnetic Stimulation (TMS) for treating depression (搜索), including suicidal depression (搜索). This expansion represents a promising new indication for the Breakthrough Therapy-designated drug that could offer a rapid path to commercialization.
Clinical Evidence Supporting Combination Therapy
Recent clinical evidence demonstrates significant therapeutic advantages when D-cycloserine is combined with TMS. Cole and colleagues reported that patients randomized to D-cycloserine versus placebo concurrent with TMS using a standard protocol experienced greater than two-fold benefit in terms of reduction in symptoms of depression (搜索). The D-cycloserine-treated group achieved clinical response rates of 75% and remission rates of 40%.
More recent real-world data presented on November 4, 2025, showed even more promising results. The study examined a modern Theta Burst FDA-cleared TMS device combined with a one-day TMS protocol and a single administration of oral D-cycloserine. The authors reported 87% clinical response and 72% remission rates manifesting at 6 weeks after a single day of treatment on the Hamilton Depression (搜索) Rating Scale, with similar findings on other standard test measures.
Mechanism of Action and Neuroplasticity Effects
Nonclinical evidence suggests that D-cycloserine acts to augment neuroplasticity in association with TMS. A substantial body of nonclinical literature demonstrates that D-cycloserine at low doses exerts a neuroplasticity effect and causes dendritic sprouting in areas of the brain associated with depression (搜索).
The response rate from TMS with cycloserine (>80%) in these two studies compares favorably to the 30% success rate reported with SSRI antidepressants, without the well-known side effects of SSRI medications.
NRX-101 Formulation Addresses Safety Concerns
NRX-101 contains both D-cycloserine and a low dose of lurasidone, a medicine already approved for treatment of depression (搜索) with anti-hallucinatory properties. D-cycloserine by itself has a low but measurable potential for inducing low-grade hallucinations, resulting in a labeled contraindication against the use of Seromycin® (D-cycloserine) in patients with depression. This contraindication originally led NRx founders to develop and patent the NRX-101 drug combination, which has obtained composition of matter patent protection in all major jurisdictions.
Development Strategy and Market Potential
NRx believes the clinical benefit demonstrated in these two published trials can be replicated in well-controlled trials of approximately 120 participants. The company is in partnership discussions with manufacturers of currently-marketed TMS devices to configure joint clinical trials that will lead to drug registration and augmentation of FDA labeling of currently-approved TMS devices. Because TMS is already an approved and reimbursed therapy for patients with depression (搜索), the company anticipates such trials can be accomplished at modest expense.
Given current trends, NRx expects that more than 1 million Americans per year may be treated with TMS by 2030, creating a substantial new potential market for NRX-101 not previously anticipated. The company currently has more than 25,000 manufactured investigational doses available.
Expanded Access and Regulatory Status
As required by law for Breakthrough Therapy drugs such as NRX-101, the company has published an Expanded Access policy for this medication. The protocol will be available to patients both through clinical trials and under NRx's Expanded Access protocols. Treating physicians who believe their patients might benefit from NRX-101 in association with TMS may contact the company for further information.
Should the findings of these clinical studies be replicated in registration trials conducted to current regulatory standards, the company anticipates D-cycloserine or similar medicines will become standard of care therapy in association with TMS.